Novo Nordisk A/S plans to seek US regulatory approval for a high-dose version of its blockbuster weight-loss shot Wegovy, another effort to counter Eli Lilly & Co. in the booming obesity market.
High-dose Wegovy offers the same weight-loss potential as Lilly’s Zepbound, giving patients another option, said Martin Holst Lange, Novo’s chief scientific officer. Though the drugmaker hasn’t yet formally announced its US plans, it intends to file for Food and Drug Administration approval, he said on Tuesday at the European Association for the Study of Diabetes conference in Vienna.